Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 10/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.47 |
| ▸ | INSR | P06213 | 5/20 | 0.47 |
| ▸ | CDK7 | P50613 | 3/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.47 |
| ▸ | PLK4 | O00444 | 2/20 | 0.47 |
| ▸ | GAK | O14976 | 2/20 | 0.47 |
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | STK10 | O94804 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | FES | P07332 | 2/20 | 0.47 |
| ▸ | YES1 | P07947 | 2/20 | 0.47 |
| ▸ | IGF1R | P08069 | 2/20 | 0.47 |
| ▸ | HCK | P08631 | 2/20 | 0.47 |
| ▸ | ROS1 | P08922 | 2/20 | 0.47 |
| ▸ | FER | P16591 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19867326 | 0.93 | ALK (0.52) | ALKIRAK4PTK2LRRK2MET | |
| SCHEMBL21150135 | 0.89 | ALK (0.64) | ALKIRAK4PTK2INSRCDK7 | |
| SCHEMBL21150115 | 0.88 | ALK (0.63) | ALKIRAK4PTK2INSRCDK7 | |
| SCHEMBL21150898 | 0.86 | ALK (0.56) | ALKIRAK4PTK2INSRCDK7 | |
| SCHEMBL19867185 | 0.82 | ALK (0.63) | ALKIRAK4PTK2INSRCDK7 | |
| SCHEMBL19867368 | 0.81 | PDE5A (0.56) | ALKPTK2INSRMETJAK2 | |
| SCHEMBL21100192 | 0.80 | ALK (0.65) | ALKIRAK4PTK2INSRCDK7 | |
| SCHEMBL19867208 | 0.79 | ALK (0.54) | ALKIRAK4PTK2CDK7FES | |
| SCHEMBL21150935 | 0.78 | ALK (0.82) | ALKIRAK4PTK2INSRCDK7 | |
| SCHEMBL19867212 | 0.77 | ALK (0.61) | ALKIRAK4PTK2CDK7ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | Hongyun Biotech Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | disclosed |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | ALK 1/4885IRAK4 701/4885PTK2 141/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | ALK 1/4885IRAK4 701/4885PTK2 141/4885 |
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | ALK, MET, TIE1 | ALK 1/4885IRAK4 701/4885PTK2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.